London, United Kingdom-Monday 1 November 2021 [ AETOS Wire ]
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has entered into an exclusive licensing agreement with Almirall S.A., a global biopharmaceutical company, to commercialise FinjuveTM in certain Middle East and North Africa (MENA) markets.
FinjuveTM is a finasteride spray that is approved in Italy, Germany, Luxembourg and Portugal for the treatment of androgenetic alopecia.
Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in certain MENA markets and Almirall will be responsible for product supply.
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA said, “We are excited to partner with Almirall and bring FinjuveTM to our androgenetic alopeci
...
Read more »